105 results match your criteria: "Institut Jules Bordet-Universite libre de Bruxelles[Affiliation]"
Curr Opin Oncol
January 2025
Department of Medical Oncology, Institut Jules Bordet - Université Libre de Bruxelles (ULB).
Purpose Of Review: This review aims to explore the evolving management strategies for stage III melanoma, focusing on the comparative effectiveness of traditional surgical approaches like complete lymph node dissection (CLND) versus modern adjuvant therapies. It also examines the latest evidence on the efficacy, risks, and complications of these strategies, emphasizing the role of shared decision-making between patients and clinicians.
Recent Findings: Recent clinical trials and meta-analyses, including the MSLT-II and DeCOG-SLT studies, have demonstrated that CLND may not significantly improve survival outcomes in melanoma patients with sentinel lymph node biopsy (SLNB)-positive status.
Pract Radiat Oncol
January 2025
Department of Radiation-Oncology, Institut Jules Bordet - Université Libre de Bruxelles, Brussels, Belgium. Electronic address:
Clin Case Rep
December 2024
Department of Stomatology, Oral & Maxillofacial Surgery CHU Saint Pierre Brussels Belgium.
This case report contributes to understanding the complexities of ameloblastoma recurrence despite meeting recommended guidelines and highlights the importance of long-term follow-up and tailored surgical approaches.
View Article and Find Full Text PDFJ Clin Oncol
October 2024
Medical Oncology, Texas Oncology-Baylor Charles A. Sammons Cancer Center, Dallas, TX.
Purpose: Human epidermal growth factor receptor 2 (HER2)-targeted therapy is standard of care for HER2-positive (HER2+) breast cancer, but most patients develop progressive disease with persistent HER2 expression. No definitive treatment guidance currently exists beyond second line. Trastuzumab duocarmazine (T-Duo) is a third-generation, HER2-targeted antibody-drug conjugate that demonstrated efficacy and acceptable safety in phase I studies of heavily pretreated patients with HER2+/HER2-low breast cancer.
View Article and Find Full Text PDFPhys Imaging Radiat Oncol
October 2024
Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.
Multiple tools are available for commissioning and quality assurance of deformable image registration (DIR), each with their own advantages and disadvantages in the context of radiotherapy. The selection of appropriate tools should depend on the DIR application with its corresponding available input, desired output, and time requirement. Discussions were hosted by the ESTRO Physics Workshop 2021 on Commissioning and Quality Assurance for DIR in Radiotherapy.
View Article and Find Full Text PDFClin Cancer Res
October 2024
University of Texas Health Sciences Center, San Antonio, Texas.
Curr Opin Oncol
July 2024
Department of Medical Oncology, Institut Jules Bordet - Université Libre de Bruxelles (ULB), Brussels, Belgium.
Purpose Of Review: This review is timely and relevant due to the increasing recognition of the significance of the fibroblast growth factor receptor (FGFR) family in cancer biology. Understanding the role of FGFRs and their dysregulation in various cancers is crucial for developing targeted therapies and improving patient outcomes.
Recent Findings: The review highlights the importance of the FGFR family in cellular processes such as growth, proliferation, and survival.
Lancet Oncol
June 2024
Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.
Clin Case Rep
April 2024
Department of Intensive Care and Oncological Emergencies & Thoracic Oncology, Institut Jules Bordet Université Libre de Bruxelles Brussels Belgium.
Key Clinical Message: Clinical presentation of leukemia cutis (LC) is polymorphic and can reveal a malignant hemopathy. More commonly described in cases of acute myeloid leukemia (AML), LC can also occur in case of chronic myeloid leukemia (CML).
Abstract: Leukemia cutis is a rare form of extramedullary feature of malignant hemopathy, seldom associated with CML.
BMC Biol
January 2024
Laboratory of Evolutionary Genetics and Ecology (LEGE), Department of Biology - URBE, University of Namur, Rue de Bruxelles, 61, B-5000, Namur, Belgium.
Background: The remarkable resistance to ionizing radiation found in anhydrobiotic organisms, such as some bacteria, tardigrades, and bdelloid rotifers has been hypothesized to be incidental to their desiccation resistance. Both stresses produce reactive oxygen species and cause damage to DNA and other macromolecules. However, this hypothesis has only been investigated in a few species.
View Article and Find Full Text PDFESMO Open
December 2023
Department of Medical Oncology, UZ Brussel, Brussels; Department of Medical Genetics, UZ Brussel, Brussels, Belgium.
Background: The Belgian Precision initiative aims to maximize the implementation of tumor-agnostic next-generation sequencing in patients with advanced cancer and enhance access to molecularly guided treatment options. Academic tumor-agnostic basket phase II studies are part of this initiative. The current investigator-driven trial aimed to investigate the efficacy of olaparib in advanced cancers with a (likely) pathogenic mutation (germline or somatic) in a gene that plays a role in homologous recombination (HR).
View Article and Find Full Text PDFPhys Med Biol
October 2023
The Netherlands Cancer Institute, Department of Radiation Oncology, Amsterdam, The Netherlands.
A subcommittee of the Netherlands Commission on Radiation Dosimetry (NCS) was initiated in 2018 with the task to update and extend a previous publication (NCS-15) on the quality assurance of treatment planning systems (TPS) (Bruinvis2005). The field of treatment planning has changed considerably since 2005. Whereas the focus of the previous report was more on the technical aspects of the TPS, the scope of this report is broader with a focus on a department wide implementation of the TPS.
View Article and Find Full Text PDFEBioMedicine
August 2023
Institute of Human Genetics, University of Marburg, Marburg, Germany. Electronic address:
Radiat Oncol
June 2023
Institut Jules Bordet, Department of Radiation-Oncology, Université Libre de Bruxelles, Brussels, Belgium.
Purpose / Objective: This study compares the dosimetric plans of three distinct boost modalities in cervical cancer (CC): intracavitary (IC) with tandem/ovoids brachytherapy (BT), IC + interstitial (IS) BT, and Stereotactic-Body-Radiotherapy (SBRT). The aim is to determine the dosimetric impact in terms of target coverage and organ at risk (OAR) doses.
Materials And Methods: 24 consecutive IC + IS BT boost treatment plans were retrospectively identified.
Breast Cancer Res Treat
August 2023
Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, MA, 02114, USA.
EBioMedicine
June 2023
Institute of Human Genetics, University of Marburg, Marburg, Germany. Electronic address:
Background: Gastric cancer (GC) is clinically heterogenous according to location (cardia/non-cardia) and histopathology (diffuse/intestinal). We aimed to characterize the genetic risk architecture of GC according to its subtypes. Another aim was to examine whether cardia GC and oesophageal adenocarcinoma (OAC) and its precursor lesion Barrett's oesophagus (BO), which are all located at the gastro-oesophageal junction (GOJ), share polygenic risk architecture.
View Article and Find Full Text PDFJAMIA Open
July 2023
Department of Medicine and Health Sciences Vincenzo Tiberio, University of Molise, Campobasso, Italy.
Objective: Soft-tissue sarcomas (STSs) of the extremities are a group of malignancies arising from the mesenchymal cells that may develop distant metastases or local recurrence. In this article, we propose a novel methodology aimed to predict metastases and recurrence risk in patients with these malignancies by evaluating magnetic resonance radiomic features that will be formally verified through formal logic models.
Materials And Methods: This is a retrospective study based on a public dataset evaluating MRI scans T2-weighted fat-saturated or short tau inversion recovery and patients having "metastases/local recurrence" (group B) or "no metastases/no local recurrence" (group A) as clinical outcomes.
Cold Spring Harb Mol Case Stud
April 2023
Clinical Trials Conduct Unit, Institut Jules Bordet-Université Libre de Bruxelles, Brussels, 1070, Belgium
As wider insights are gained on the molecular landscape of triple-negative breast cancer (TNBC), novel targeted therapeutic strategies might become an option in this setting as well. Activating mutations of represent the second most common alteration in TNBC after the mutation, with a prevalence of ∼10%-15%. Considering the well-established predictive role of mutations for response to agents targeting the PI3K/AKT/mTOR pathway, several clinical trials are currently evaluating these drugs in patients with advanced TNBC.
View Article and Find Full Text PDFBr J Cancer
February 2023
Medical Oncology, ENETS Centre of Excellence, Royal North Shore Hospital, Sydney, NSW, Australia.
Background: Gastroenteropancreatic neuroendocrine neoplasms (GEPNENs) are heterogeneous in clinical course, biology, and outcomes. The NETPET score predicts survival by scoring uptake on dual [Ga]DOTATATE and [F]FDG PET/CT scans. We aimed to validate previous single-centre findings in a multicentre, international study.
View Article and Find Full Text PDFPhys Med
November 2022
Radiology Department, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium.
Purpose: The aim of this study was to perform a quantitative quality assurance of diffusion-weighted MRI to assess the variability of the mean apparent diffusion coefficient (ADC) and other radiomic features across the scanners involved in the REGINA trial.
Materials And Methods: The NIST/QIBA diffusion phantom was acquired on six 3 T scanners from five centres with a rectum-specific diffusion protocol. All sequences were repeated in each scan session without moving the phantom from the table.
Future Oncol
October 2022
Medica Scientia Innovation Research (MEDSIR), Barcelona, Spain.
What Is This Summary About?: This is a summary of a publication about the PHERGain study, which was published in in May 2021. The study includes 376 women with a type of breast cancer called HER2-positive breast cancer that can be removed by surgery. In the study, researchers wanted to learn if participants could be treated with two medicines called trastuzumab and pertuzumab without the need for chemotherapy.
View Article and Find Full Text PDFEur J Nucl Med Mol Imaging
February 2023
Centre de Recherche de L'Inflammation (CRI), Université Paris Cité, INSERM U1149, Paris, France.
Background: A textbook outcome (TO) is a composite indicator covering the entire intervention process in order to reflect the "ideal" intervention and be a surrogate for patient important outcomes. Selective internal radiation therapy (SIRT) is a complex multidisciplinary and multistep intervention facing the challenge of standardization. This expert opinion-based study aimed to define a TO for SIRT of hepatocellular carcinoma.
View Article and Find Full Text PDFRep Pract Oncol Radiother
July 2022
Department of Radiation-Oncology, CHU UCL Namur, Site Saint-Elisabeth, Namur, Belgium.
Background: In our department, during lung stereotactic body radiation therapy (SBRT), all patients receive an intra-fractional midpoint cone beam computed tomography (CBCT). This study aimed to quantify the benefit of adding a second midpoint CBCT over a course of peripheral lung SBRT.
Materials And Methods: Six-hundred-sixty-four CBCTs from 166 patients were retrospectively analyzed.
Front Oncol
August 2022
Department of Radiation-Oncology, Institut Jules Bordet-Université Libre de Bruxelles, Brussels, Belgium.
Purpose/objective: Deep Inspiration Breath Hold (DIBH) is now considered as the standard of care for many breast cancer patients. However, there are still uncertainties about the dose given to the heart, and it is unknown if patients may improve voluntary DIBH depth by gaining experience during treatment. In this study, we will examine the interfractional three-dimensional (3D) heart displacement throughout voluntary DIBH (vDIBH) radiotherapy by means of daily cone-beam computed tomography (CBCT).
View Article and Find Full Text PDFBiomed Phys Eng Express
September 2022
Medical Physics Department, Institut Jules Bordet - Université Libre de Bruxelles, Brussels, Belgium.
Introduction: Radiomics is a promising imaging-based tool which could enhance clinical observation and identify representative features. To avoid different interpretations, the Image Biomarker Standardisation Initiative (IBSI) imposed conditions for harmonisation. This study evaluates IBSI-compliant radiomics applications against a known benchmark and clinical datasets for agreements.
View Article and Find Full Text PDF